Literature DB >> 33335419

MAGGIC Risk Model Predicts Adverse Events and Left Ventricular Remodeling in Non-Ischemic Dilated Cardiomyopathy.

Yang Dong1, Dongfei Wang1, Jialan Lv1, Zhicheng Pan1, Rui Xu1, Jie Ding1, Xiao Cui1, Xudong Xie1, Xiaogang Guo1.   

Abstract

PURPOSE: We aimed to study the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) risk model's prognostic value and relationship with left ventricular remodeling in dilated cardiomyopathy. PATIENTS AND METHODS: Dilated cardiomyopathy patients were prospectively recruited and underwent clinical assessments. MAGGIC risk score was calculated. Patients were followed up for adverse events and echocardiography. Primary endpoints were all-cause mortality and first rehospitalization due to heart failure. Secondary endpoint was left ventricular remodeling defined as a decline in left ventricular ejection fraction >10% or an increase in left ventricular end-diastolic diameter >10%. Survival status was examined using Cox regression analysis. The model's ability to discriminate adverse events and left ventricular remodeling was calculated using a receiver operating characteristics curve.
RESULTS: In total, 114 patients were included (median follow-up time = 31 months). The risk score was independently related to adverse events (2-year all-cause mortality: hazard ratio [HR] = 1.122; 95% confidence interval [CI], 1.043-1.208; 1-year first rehospitalization due to heart failure: HR = 1.094; 95% CI, 1.032-1.158; 2-year first rehospitalization due to heart failure: HR = 1.088; 95% CI, 1.033-1.147, all P < 0.05). One-year change in left ventricular end-diastolic diameter was correlated with the risk score (r = 0.305, P = 0.002). The model demonstrated modest ability in discriminating adverse events and left ventricular remodeling (all areas under the curve were 0.6-0.7).
CONCLUSION: The MAGGIC risk score was related to adverse events and left ventricular remodeling in dilated cardiomyopathy.
© 2020 Dong et al.

Entities:  

Keywords:  dilated cardiomyopathy; left ventricular remodeling; prognosis; risk model

Year:  2020        PMID: 33335419      PMCID: PMC7736706          DOI: 10.2147/IJGM.S288732

Source DB:  PubMed          Journal:  Int J Gen Med        ISSN: 1178-7074


  35 in total

Review 1.  Dilated cardiomyopathy.

Authors:  Robert G Weintraub; Christopher Semsarian; Peter Macdonald
Journal:  Lancet       Date:  2017-02-10       Impact factor: 79.321

2.  Gender medicine in dilated cardiomyopathy: pride and prejudice.

Authors:  Gianfranco Sinagra; Marco Merlo; Antonio Cannatà
Journal:  Eur J Heart Fail       Date:  2018-08-09       Impact factor: 15.534

3.  Abnormal Circadian Blood Pressure Profile as a Prognostic Marker in Patients with Nonischemic Dilated Cardiomyopathy.

Authors:  Akinori Sawamura; Takahiro Okumura; Kyosuke Takeshita; Naoki Watanabe; Naoaki Kano; Hiroaki Mori; Kenji Fukaya; Ryota Morimoto; Akihiro Hirashiki; Yasuko Kureishi Bando; Toyoaki Murohara
Journal:  Cardiology       Date:  2016-08-19       Impact factor: 1.869

4.  Left ventricular reverse remodelling predicts long-term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry.

Authors:  Marianna Adamo; Cosmo Godino; Cristina Giannini; Andrea Scotti; Riccardo Liga; Salvatore Curello; Claudia Fiorina; Ermanna Chiari; Giuliano Chizzola; Alessandro Abbenante; Emanuele Visco; Luca Branca; Francesca Fiorelli; Eustachio Agricola; Stefano Stella; Carlo Lombardi; Antonio Colombo; Anna Sonia Petronio; Marco Metra; Federica Ettori
Journal:  Eur J Heart Fail       Date:  2018-12-13       Impact factor: 15.534

5.  Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.

Authors:  Carlos G Santos-Gallego; Juan Antonio Requena-Ibanez; Rodolfo San Antonio; Kiyotake Ishikawa; Shin Watanabe; Belen Picatoste; Eduardo Flores; Alvaro Garcia-Ropero; Javier Sanz; Roger J Hajjar; Valentin Fuster; Juan J Badimon
Journal:  J Am Coll Cardiol       Date:  2019-04-23       Impact factor: 24.094

6.  Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy.

Authors:  Matteo Dal Ferro; Davide Stolfo; Alessandro Altinier; Marta Gigli; Martina Perrieri; Federica Ramani; Giulia Barbati; Alberto Pivetta; Francesca Brun; Lorenzo Monserrat; Mauro Giacca; Luisa Mestroni; Marco Merlo; Gianfranco Sinagra
Journal:  Heart       Date:  2017-04-17       Impact factor: 5.994

Review 7.  Sudden cardiac death in non-ischemic dilated cardiomyopathy: a critical appraisal of existing and potential risk stratification tools.

Authors:  Emmanuel Koutalas; Emmanuel Kanoupakis; Panos Vardas
Journal:  Int J Cardiol       Date:  2012-08-11       Impact factor: 4.164

8.  Incremental value of right heart metrics and exercise performance to well-validated risk scores in dilated cardiomyopathy.

Authors:  Kegan J Moneghetti; Genevieve Giraldeau; Matthew T Wheeler; Yukari Kobayashi; Bojan Vrtovec; David Boulate; Tatiana Kuznetsova; Ingela Schnittger; Joseph C Wu; Jonathan Myers; Euan Ashley; Francois Haddad
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2018-08-01       Impact factor: 6.875

9.  Risk Prediction in Transition: MAGGIC Score Performance at Discharge and Incremental Utility of Natriuretic Peptides.

Authors:  Alexander Michaels; Lindsey Aurora; Edward Peterson; Bin Liu; Yigal M Pinto; Hani N Sabbah; Keoki Williams; David E Lanfear
Journal:  J Card Fail       Date:  2019-11-18       Impact factor: 5.712

10.  Age and Gender Impact the Measurement of Myocardial Interstitial Fibrosis in a Healthy Adult Chinese Population: A Cardiac Magnetic Resonance Study.

Authors:  Yang Dong; Dan Yang; Yuchi Han; Wei Cheng; Jiayu Sun; Ke Wan; Hong Liu; Andreas Greiser; Xiaoyue Zhou; Yucheng Chen
Journal:  Front Physiol       Date:  2018-03-06       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.